International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Bristol Myers Squibb Announces the Committee for Medicinal Products for Human Use (CHMP) has Recommended the Approval of Sotyktu (Deucravacitinib) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

Psoriasis News BMS Blog Graphic

Bristol Myers Squibb (BMS) announced the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for once-daily Sotyktu (deucravacitinib) as a treatment for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. The CHMP decision was based on results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 trials and an additional two years of data from the POETYK PSO long-term extension trial. The CHMP recommendation will be reviewed by the European Commission, and if approved, Sotyktu would be the first oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor in the European Union for the treatment of any disease.

bristol myers squibb logo


Recent Posts

Shining a Spotlight: Catching up with 2021 IPC Fellow Álvaro González-Cantero MD, PhD

Getting to Know IPC’s Board Member Andrew Blauvelt: What Inspired Me to Specialize in Psoriasis

Commentary -Tiago Torres

Commentary: Single-cell and Spatial Transcriptomics Analysis of Psoriasis Skin Lesions After IL-23 Inhibition

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.